Breaking News, Collaborations & Alliances

Lilly, Hanmi Enter Immunology License and Collaboration

To develop and commercialize Hanmi's oral BTK inhibitor

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Eli Lilly and Co. and Hanmi Pharmaceutical Co., Ltd. have entered an exclusive license and collaboration agreement for the development and commercialization of Hanmi’s oral Bruton’s tyrosine kinase (BTK) inhibitor, HM71224, for the treatment of autoimmune and other diseases. HM71224 is ready to enter Phase II trials and will be investigated for the potential treatment of rheumatoid arthritis, lupus, lupus nephritis, Sjögren’s syndrome, and other related conditions.   Lilly will...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters